Beam Therapeutics Inc. (BEAM)
BEAMNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$27.50
+1.09 (+4.13%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $2.80bn
- P/E
- –
- EPS, last 4 quarters
- $-3.47
- Dividend yield
- –
- Day range
- –
- 52-week range
- $20.23 to $38.26
- Average volume
- 1.87m
- Previous close
- $26.41
Analysts
13 coveringBuy12 buy, 1 hold, 0 sell
Targets a year out average $49.08, +78.5% from here
Earnings
next estimate $-1.29Next report
Dec 2025
+91.2%
Mar 2026
-4.6%
Jun 2026
-18.0%
Sep 2026
-9.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $114.11m | $31.74m | $490.0k | $307.0k |
| Gross profit | $114.11m | $31.74m | $490.0k | $307.0k |
| Operating income | -$17.45m | -$107.22m | -$126.55m | -$141.32m |
| Net income | $243.05m | -$94.32m | -$122.68m | -$134.41m |
Last four quarters: revenue $146.64m, margin -73.9%, free cash flow -$398.24m
News
8 latest- Beam Therapeutics Inc. Reports Third Quarter 2026 Financial Results and Clinical ProgressFintel · 6 days ago
- Beam Therapeutics Plans BEAM-304 Phase 1/2 Trial In PKU For Early 2027; Stock Up RTTNews · 6 days ago
- Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue EstimatesZacks · 7 days ago
- Beam Therapeutics Inc. Q3 Loss Widens RTTNews · 7 days ago
- 3 Promising Genomics Stocks to Add to Your Portfolio Now Zacks · Oct 30, 2026
- Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks · Oct 29, 2026
- Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?Zacks · Oct 29, 2026
- Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting ToleranceMarketBeat · Oct 27, 2026
The company
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- beamtx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.